153 related articles for article (PubMed ID: 21648216)
1. First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data.
Prescrire Int; 2011 Apr; 20(115):101-4. PubMed ID: 21648216
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
3. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
4. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
Kline MW; Rugina S; Ilie M; Matusa RF; Schweitzer AM; Calles NR; Schwarzwald HL
Pediatrics; 2007 May; 119(5):e1116-20. PubMed ID: 17420261
[TBL] [Abstract][Full Text] [Related]
8. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
9. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
11. HIV exposure through contact with body fluids.
Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral drug resistance among HIV-1 infected children failing treatment.
Mullen J; Leech S; O'Shea S; Chrystie IL; Du Mont G; Ball C; Sharland M; Cottam F; Zuckerman M; Rice P; Easterbrook P
J Med Virol; 2002 Nov; 68(3):299-304. PubMed ID: 12226814
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
15. Treating an HIV-infected paediatric patient: an easy task?
Rakhmanina NY; van den Anker JN
Antivir Ther; 2010; 15(3):293-6. PubMed ID: 20516549
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
[TBL] [Abstract][Full Text] [Related]
17. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
18. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
[TBL] [Abstract][Full Text] [Related]
19. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
